Dec. 5 (UPI) -- Pharmaceutical giant Pfizer on Monday announced the company and its partner BioNTech have asked the U.S. Food and Drug Administration to approve an updated COVID-19 vaccine regimen for young children.
Pfizer has asked the FDA to authorize a substitution for the third shot of the regimen, replacing an extra-small dose of the vaccine with the company's bivalent vaccine that targets the Omicron variant of the virus for children under age 5.